ArticleBlood2019
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells.Oncology reports · 2026Article
- Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.Annals of hematology · 2026Observational
- Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia.Nature cancer · 2025Article
- Ivosidenib or venetoclax combined with hypomethylating agents inBlood neoplasia · 2025Article
- We still need to hit hard in acute myeloid leukemia, but only in the right patients.Haematologica · 2025Article
- Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries.Annals of hematology · 2025Article
- Analysis of temporal survival trends: considerations and best practice.BMC medical research methodology · 2025Article
- Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019.EClinicalMedicine · 2024Article
- Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century.Blood cancer journal · 2024Article
- Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?BMJ oncology · 2024Article
- Improving long-term outcomes with intensive induction chemotherapy for patients with AML.Hematology. American Society of Hematology. Education Program · 2023Article
- The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.Blood · 2023Article
- A Leukemic Target with a Thousand Faces: The Mitochondria.International journal of molecular sciences · 2023Review
- Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Blood advances · 2023Article
- Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.Journal of internal medicine · 2022Article
- DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia.Experimental hematology & oncology · 2022Article
- How I TreatCancers · 2022Review
- Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression.Blood · 2022Article
- Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.Annals of hematology · 2021Article
- Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?Haematologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.